HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates

Strickler, Howard D.; Kirk, Gregory D.; Figueroa, J. Peter; Ward, Elizabeth; Braithwaite, Alfred R.; Escoffery, Carlos; Drummond, James E.; Goebel, Brad; Waters, David J.; McClimens, Roberta; Manns, Angela

doi:10.1002/(sici)1097-0215(19990129)80:3<339::aid-ijc1>3.0.co;2-f

Cited by 42 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The seroprevalence peak is also 10 -20 years after sexual initiation, thus potentially mirroring the effect of multiple lifetime sexual partners, which correlates with age. However, unlike other studies, we did not observe an increase in HPV seropositivity with age (Strickler et al, 1999;Studentsov et al, 2002). On the contrary, the slight decrease of seropositivity observed in our older age groups supports the suggested waning of seropositivity over time and the imperfect nature of serology as a measure of cumulative exposure; alternatively, this could reflect a cohort effect.…”

Section: Discussioncontrasting

confidence: 93%

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

et al. 2003

View full text Add to dashboard Cite

Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10 049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n ¼ 9949), HPV-18 (n ¼ 9928), HPV-31 (n ¼ 9932), and HPV-45 (n ¼ 3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n ¼ 573). 15, 16, and 11%, respectively. Of women DNA-positive for , seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA-and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women. British Journal of Cancer (2003) (Ho et al, 1995). The prevalence of HPV DNA therefore underestimates the cumulative incidence of infection in a population, particularly where the majority of women will not develop persistent infection or cervical neoplasia. Measurement of serum antibody to HPV capsids (or virus-like particles (VLPs)) has been demonstrated as a useful although imperfect marker of past and cumulative HPV exposure, thus complementing the assessment of HPV DNA (Kirnbauer et al, 1994;Wideroff et al, 1995Wideroff et al, , 1999Carter et al, 1996;Sasagawa et al, 1998;Touze et al, 2001).As part of a large population-based study of the natural history of HPV infection and cervical neoplasia in Guanacaste, Costa Rica, we report here the population-based seroprevalence in Guanacaste women of four oncogenic HPV types found in the majority of cervical cancers worldwide Munoz et al, 2003). The data presented document the baseline burden of HPV exposure in Guanacaste, Costa Rica. As a major objective, we determined the association of risk for concurrent diagnosis of CIN3/cancer with HPV assessed jointly by serology and PCR-based DNA testing. As only about half of all HPV-DNA-positive women are seropositive using available VLP assays (Kirnbauer et al, 1994;Le Cann et al, 1995), we also investigated determinants of seropositivity in our population. METHODS Study populationThis study was conducted in an on-going population-based cohort study of 10 049 women in Guanacaste, Costa Rica (Herrero et al, 1997;Hildesheim et al, 2001) who were enrolled in 1993 -1994 with the approval of the National Cancer Institute (NCI) and local institutional review boards; all participants provided written informed consent. Briefly, the cohort was a representative sample of the adult population based on selection by cluster sampling, with oversampling for cancer. Participation among eligible women exceeded 90%, and participants completed a risk factor questionnaire that addressed demographic, behavioural, and sexual practices. Women were screened using three cytologic and one visual test at enrollment; colposcopy referral with biopsy was perform...

show abstract

Section: Discussioncontrasting

confidence: 93%

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Men ages 36 to 44 years were four times more likely to be seropositive than men ages 18 to 25 years. In previous studies, age has been positively associated with seroprevalence in both men and women (5,7,(18)(19)(20)(21). In two studies that included participants across a broad age range, an inverse U-shaped association with age was reported, with seroprevalence peaking at age 35 to 49 years and declining with increasing age afterwards (18,19).…”

Section: Discussionmentioning

confidence: 87%

“…A limited number of studies have evaluated the prevalence of HPV 16 serum antibodies and its determinants, and fewer have evaluated the prevalence of serum antibodies to other HPV types. Among 21 published studies that investigated serum antibodies to HPV 16 L1 virus-like particles (VLP) and factors associated with HPV 16 seropositivity, only 9 enrolled men (1)(2)(3)(4)(5)(6)(7)(8)(9). Only two published studies to date have examined the potential protective role of serum antibodies in subsequent infection in women (10,11) and none have been conducted in men.…”

Section: Introductionmentioning

confidence: 99%

Epidemiologic Factors Associated with Seropositivity to Human Papillomavirus Type 16 and 18 Virus–Like Particles and Risk of Subsequent Infection in Men

Hagensee

Lee

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Our understanding of humoral response to human papillomavirus (HPV) infection has been mainly derived from studies in women. The role of serum antibodies in the natural history of HPV in men has yet to be investigated. Data from 285 male participants of a natural history study were used to determine the epidemiologic factors associated with HPV 16/18 seropositivity and explore the role of HPV 16 and 18 serum antibodies in subsequent HPV infections. Serum antibodies were detected by use of HPV 16-and 18 virus-like particles enzyme-linked immunoassay. Logistic regression and Generalized Estimating Equation was used for the evaluation of risk factors. The risk of subsequent HPV infection by baseline antibody status was assessed by incidence rate ratio and its confidence intervals. Men ages 36 to 44 years compared with men ages 18 to 25 years were four times more likely to be seropositive to HPV 16/18. In addition, being divorced, separated, or widowed; being a former smoker; and having sex with men was positively and independently associated with HPV 16/18 seropositivity. Our findings on the potential role of HPV 16 or 18 serum antibodies in subsequent infection were inconclusive. Large prospective studies are warranted to adequately address questions on the role of natural immunity in the natural history of HPV infections in men. Cancer Epidemiol Biomarkers Prev; 19(2); 511-6. ©2010 AACR.

show abstract

“…Higher seroprevalence among sexually active women than sexually active men has previously been reported from various populations for HPV (6,(10)(11)(12) and also for herpes simplex virus type 2 (10,33). This discrepancy may reflect greater transience of HPV infection in male external genitalia than in the female vagina and cervix, as persistent exposure to the virus over time seems to be required for seroconversion in women (1).…”

Section: Discussionmentioning

confidence: 91%

“…HPV seroprevalence doubled to 25% among sexually active women in this study, and this increase was seen independently for each of the seven HPV types tested. Although a strong increase in HPV seropositivity with increasing number of sexual partners has been widely reported (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16), far fewer studies have allowed a comparison with women reporting to be nonsexually active (6,29).…”

Section: Discussionmentioning

confidence: 99%

Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea

Clifford

Shin

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

111

102

View full text Add to dashboard Cite

In the absence of genital samples, human papillomavirus (HPV) serology may be useful to assess HPV infection in young men and women. HPV seroprevalence and determinants of seropositivity were assessed in 817 female and 518 male university students in Busan, South Korea, of whom 74% and 44%, respectively, reported never having had penetrative sexual intercourse. Type-specific HPV DNA status, assessed by a short PCR fragment primer set, was available from genital samples. Seropositivity to L1 proteins of HPV types 16, 18, 31, 33, 45, 52, and 58 were assessed using multiplex HPV serology. Among women, HPV seroprevalence was significantly higher among sexually active (26.1%) than nonsexually active students [11.1%, odds ratio (OR) = 2.9; 95% confidence interval (95% CI), 1.8-4.7], although the association was weaker than that for HPV DNA prevalence (OR, 14; 95% CI, 4.7-42). Furthermore, HPV seroprevalence was higher among HPV DNA-positive (24%) than HPV DNAnegative women (13%), and there was a positive correlation of type-specific seroprevalence with the presence of HPV DNA of the same type. In contrast, HPV seropositivity among men was not associated with sexual behavior or the presence of HPV DNA. Seroprevalence correlates with genital HPV exposure in young women, but its meaning in young men is unclear.

show abstract

HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates

Cited by 42 publications

References 20 publications

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

Epidemiologic Factors Associated with Seropositivity to Human Papillomavirus Type 16 and 18 Virus–Like Particles and Risk of Subsequent Infection in Men

Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea

Contact Info

Product

Resources

About